Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Brexanolone

FDA-approved product (solution, intravenous), marketed as Zulresso.

Registered studies
26
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Brexanolone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Depressive disorder
  • Major depressive disorder
  • Postpartum depression

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antidepressants
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli10.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae24.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis23.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

26registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Brexanolone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.6 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.0 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Brexanolone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Study to Evaluate Efficacy and Safety of SAGE-547 in Participants With Severe Postpartum Depression (547-PPD-202B)

    NCT02942004 · start 2016-08-01

    Registered record
    Registry ID
    NCT02942004
    Conditions
    Postpartum Depression
    Interventions
    Placebo; SAGE-547 60 μg/kg/h; SAGE-547 90 μg/kg/h
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-08-01
    Completion
    2017-10-19
    Enrolment
    138

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostpartum Depression
    InterventionPlacebo; SAGE-547 60 μg/kg/h; SAGE-547 90 μg/kg/h
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate Safety and Efficacy of SAGE-547 in Participants With Moderate Postpartum Depression (547-PPD-202C)

    NCT02942017 · start 2016-07

    Registered record
    Registry ID
    NCT02942017
    Conditions
    Postpartum Depression
    Interventions
    Placebo; SAGE-547 90 μg/kg/h
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2016-07
    Completion
    2017-10-11
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostpartum Depression
    InterventionPlacebo; SAGE-547 90 μg/kg/h
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate SAGE-547 in Participants With Severe Postpartum Depression

    NCT02614547 · start 2015-12-15

    Registered record
    Registry ID
    NCT02614547
    Conditions
    Severe Postpartum Depression
    Interventions
    SAGE-547; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-12-15
    Completion
    2016-06-22
    Enrolment
    21

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Postpartum Depression
    InterventionSAGE-547; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

    NCT02603926 · start 2015-10

    Registered record
    Registry ID
    NCT02603926
    Conditions
    Fragile X-associated Tremor/Ataxia Syndrome
    Interventions
    Allopregnanolone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-10
    Completion
    2017-12
    Enrolment
    6

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFragile X-associated Tremor/Ataxia Syndrome
    InterventionAllopregnanolone
    PhasePhase 2
    Registry statusCompleted

  • A Study With SAGE-547 for Super-Refractory Status Epilepticus

    NCT02477618 · start 2015-06

    Registered record
    Registry ID
    NCT02477618
    Conditions
    Super-Refractory Status Epilepticus
    Interventions
    SAGE-547; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2015-06
    Completion
    2017-08-11
    Enrolment
    132

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuper-Refractory Status Epilepticus
    InterventionSAGE-547; Placebo
    PhasePhase 3
    Registry statusCompleted

  • Evaluate SAGE-547 in Female Participants With Severe Postpartum Depression

    NCT02285504 · start 2015-01-07

    Registered record
    Registry ID
    NCT02285504
    Conditions
    Postpartum Depression
    Interventions
    SAGE-547
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2015-01-07
    Completion
    2015-06-05
    Enrolment
    4

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostpartum Depression
    InterventionSAGE-547
    PhasePhase 2
    Registry statusCompleted

  • Evaluate SAGE-547 in Participants With Essential Tremor

    NCT02277106 · start 2014-09-23

    Registered record
    Registry ID
    NCT02277106
    Conditions
    Essential Tremor
    Interventions
    SAGE-547; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2014-09-23
    Completion
    2015-08-14
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEssential Tremor
    InterventionSAGE-547; Placebo
    PhasePhase 2
    Registry statusCompleted

  • Study to Evaluate SAGE-547 Injection as Adjunctive Therapy for the Treatment of Super-Refractory Status Epilepticus

    NCT02052739 · start 2014-03-21

    Registered record
    Registry ID
    NCT02052739
    Conditions
    Super-refractory Status Epilepticus
    Interventions
    SAGE-547
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Completed
    Start
    2014-03-21
    Completion
    2015-05-03
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuper-refractory Status Epilepticus
    InterventionSAGE-547
    PhasePhase 1 / Phase 2
    Registry statusCompleted

  • National Pregnancy Registry for Psychiatric Medications

    NCT01246765 · start 2008-11

    Registered record
    Registry ID
    NCT01246765
    Conditions
    Pregnant Women; Psychotropic Drugs
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Recruiting
    Start
    2008-11
    Completion
    2033-12
    Enrolment
    5,000

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnant Women; Psychotropic Drugs
    InterventionNot recorded
    PhaseNot recorded
    Registry statusRecruiting

  • An Open Label, Expanded Access Protocol With SAGE-547 for Super-Refractory Status Epilepticus

    NCT02433314

    Registered record
    Registry ID
    NCT02433314
    Conditions
    Super-Refractory Status Epilepticus
    Interventions
    SAGE-547
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    No longer available
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSuper-Refractory Status Epilepticus
    InterventionSAGE-547
    PhaseNot recorded
    Registry statusNo longer available

  • Expanded Access Protocol of ZULRESSO™ (Brexanolone) Injection for Adult Patients With Postpartum Depression

    NCT03924492

    Registered record
    Registry ID
    NCT03924492
    Conditions
    Postpartum Depression
    Interventions
    ZULRESSO (brexanolone) injection
    Study type
    EXPANDED_ACCESS
    Phase
    Not recorded
    Registry status
    Approved for marketing
    Start
    Not recorded
    Completion
    Not recorded
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPostpartum Depression
    InterventionZULRESSO (brexanolone) injection
    PhaseNot recorded
    Registry statusApproved for marketing